Valuation: BioNTech SE

Market Cap 20.06B 23.16B 18.7B 17.19B 32.46B 2,202B 32.82B 220B 86.23B 1,102B 86.97B 85.05B 3,649B P/E 2026 *
-14.7x
P/E 2027 * -15.1x
Enterprise Value 9.28B 10.71B 8.65B 7.95B 15.01B 1,018B 15.18B 102B 39.88B 510B 40.23B 39.34B 1,688B EV / Sales 2026 *
5x
EV / Sales 2027 * 5.32x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day+0.91%
1 week-0.83%
Current month+1.77%
1 month-5.50%
3 months-3.48%
6 months-12.66%
Current year-3.17%
1 week 88.2
Extreme 88.2
94.41
1 month 88.2
Extreme 88.2
95.06
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
18/3/26 Other

Director

1,927 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
+0.91%-0.83%-17.01%-13.43% 23.16B
+4.35%+16.60%+58.11%+95.21% 64.9B
+2.32%+2.60%+31.48%+73.26% 54.05B
+0.27%-3.98%-11.28%+350.30% 21.46B
+1.87%+9.47%+30.87%-5.63% 21.25B
+0.71%+3.36%+38.42%-24.99% 17.94B
+9.88%+23.61%+222.87%+385.49% 17.03B
+3.29%+5.61%+21.01%+636.23% 14.99B
+1.25%+2.48%+51.36%+179.72% 14.25B
-2.99%+0.80%+427.69%+174.60% 12.28B
Average +2.19%+4.61%+85.35%+185.08% 26.13B
Weighted average by Cap. +2.62%+5.66%+62.28%+143.82%

Financials

2026 *2027 *
Net sales 1.86B 2.14B 1.73B 1.59B 3B 204B 3.04B 20.33B 7.98B 102B 8.05B 7.87B 338B 1.88B 2.17B 1.75B 1.61B 3.04B 206B 3.08B 20.59B 8.08B 103B 8.15B 7.97B 342B
Net income -1.33B -1.53B -1.24B -1.14B -2.15B -146B -2.17B -14.53B -5.7B -72.88B -5.75B -5.63B -241B -1.34B -1.55B -1.25B -1.15B -2.17B -148B -2.2B -14.72B -5.78B -73.81B -5.83B -5.7B -244B
Net Debt -10.78B -12.45B -10.05B -9.24B -17.45B -1,183B -17.64B -118B -46.34B -592B -46.74B -45.71B -1,961B -10.06B -11.61B -9.37B -8.62B -16.28B -1,104B -16.46B -110B -43.24B -552B -43.61B -42.65B -1,830B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
05/08/26 USD 92.18 +0.91% 1,700,690
04/08/26 USD 91.35 -0.98% 2,000,003
03/08/26 USD 92.25 +1.84% 1,119,580
31/07/26 USD 90.58 -2.44% 710,906
30/07/26 USD 92.85 -0.11% 1,381,280
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
79.84EUR
Average target price
104.44EUR
Spread / Average Target
+30.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock